Etiology and Management of Dyslipidemia in Patients With Cancer

Jesus, Mikhail de; Mohammed, Turab; Singh, Meghana; Tiu, John; Kim, Agnes S.

doi:10.3389/fcvm.2022.892335

Cited by 12 publications

(8 citation statements)

References 93 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the drugs used for endocrine therapy, AIs are shown to increase the risk of dyslipidemia, hyperglycemia, metabolic syndrome and hypertension, while ADTs are associated with hypertension, hyperglycemia and metabolic syndrome ( 4 ). In addition to these, other classes related to the development of dyslipidemias are anthracyclines, VEGH inhibitors, L-asparginase, JAK 1/2 inhibitor, Bexarotene, and Capcitabine ( 5 ).…”

Section: Cancer Care and Its Cardiovascular Effectsmentioning

confidence: 99%

Commentary: Longitudinal changes in circulating metabolites and lipoproteins after breast cancer treatment

Guha

Stabellini

Montero

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Section: Cancer Care and Its Cardiovascular Effectsmentioning

confidence: 99%

Commentary: Longitudinal changes in circulating metabolites and lipoproteins after breast cancer treatment

Guha

Stabellini

Montero

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

“…Chemotherapy was found to have negative impacts on quality of life and lipid levels, as reported in previous studies. [42][43][44][45] A study [46] indicated that chemotherapy caused notable changes in plasma lipid and lipoprotein levels in individuals with breast cancer, potentially through gene modulation. Intriguingly, the prevalence of liver function abnormalities was higher in US-diagnosed HS patients, compare to USE-diagnosed HS cases.…”

Section: Discussionmentioning

confidence: 99%

The prevalence of hepatic steatosis and MAFLD based on the liver ultrasound elastography in Chinese breast cancer women

Xu,

Tian,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Breast cancer is the most common malignancy in women and also shares similar risk factors with fatty liver, especially metabolic associated fatty liver disease (MAFLD). Chemotherapy can lead to hepatic impairment and hepatic steatosis (HS), which seriously affects the treatment and quality of life of breast cancer women (BCW). Therefore, this study aims to investigate the incidences of HS and MAFLD based on liver ultrasound elastography (USE), liver function abnormalities, and metabolic syndrome in Chinese BCW in the initially diagnosed, during chemotherapy and follow-up stages. Methods A total of 767 BCW treated at Chongqing Breast Cancer Centre were finally enrolled and classified into initially diagnosed group, chemotherapy group, and the follow-up group. The related conditions of HS and MAFLD as well as liver function abnormalities and metabolic syndrome were assessed by liver conventional ultrasound (US) or USE in all groups. Results Compare to US-diagnosed HS (21.7%, 36.7%, 38%), higher incidence of HS (60.4%, 78.6%, 68.0%) were detected by USE in the initially diagnosed, chemotherapy and follow-up groups. 50–70% of US-negative patients were detected by USE as having a fatty liver, which was predominantly mild to moderate. Based on the USE diagnosis, there was a higher prevalence of MAFLD in the initially diagnosed group (49.8%), which increased to 68.1% in the chemotherapy group and decreased in the follow-up group (59.1%), with a predominantly decrease of mild-to-moderate cases. BMI and age subgroups showed a higher incidence of MAFLD in patients with BMI ≥ 23 kg/m2 or age ≥ 60 years old. In addition, BCW combined with MAFLD had a higher incidence of liver function abnormalities and metabolic syndrome. Conclusion Patients treated with chemotherapy for breast cancer have a higher incidence of HS and MAFLD, especially overweight or obese and menopausal patients. Breast cancer patients with combined MAFLD have higher rates of liver function abnormalities and metabolic syndrome. USE has a higher sensitivity than US and can detect more patients with mild to moderate fatty liver disease, enabling early intervention.

show abstract

“…Higher hyperlipidemia rates were reported in patients who survived testicular cancer, suggesting that RT and/or chemotherapy also affect the lipid profile (de Jesus et al, 2022).…”

Section: Cardiovascular Adverse Effects Of Radiotherapymentioning

confidence: 96%

Brief Overview of Specific Features of Cancer in Atherosclerosis Patients and Therapeutic Strategies

Poznyak,

Orekhova,

Sukhorukov

et al. 2023

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

Cardiovascular Conditions (CVD) as well as cancer are the main death causes globally. Characteristically, there are numerous interrelations and intersections between these two groups of diseases. So, in particular, cardiovascular disease is one of the main comorbidities and death causes in cancer patients. The development of atherosclerosis is promoted by aggressive anticancer therapy regimens and various risk factors, including hypertension, lipid metabolism disorders, and others. In this review, we considered the features of the treatment of atherosclerosis and cancer in the case of their simultaneous presence.

show abstract

Etiology and Management of Dyslipidemia in Patients With Cancer

Cited by 12 publications

References 93 publications

Commentary: Longitudinal changes in circulating metabolites and lipoproteins after breast cancer treatment

Commentary: Longitudinal changes in circulating metabolites and lipoproteins after breast cancer treatment

The prevalence of hepatic steatosis and MAFLD based on the liver ultrasound elastography in Chinese breast cancer women

Brief Overview of Specific Features of Cancer in Atherosclerosis Patients and Therapeutic Strategies

Contact Info

Product

Resources

About